Table 3 Clinical response to cetuximab according to the TP53 status in 64 MCRC patients treated with cetuximab

From: TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

 

Controlled disease

 
 

Complete response

Partial response

Stable disease

Progressive disease

TP53 non-mutated

0

4

6

13

TP53 mutated

2

10

17

12

  1. Note: the TP53 status was assessed by sequencing analysis between exons 5 and 8.
  2. P=0.037 for TP53 mutations and CD vs PD.
Back to article page